JP2019521963A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521963A5 JP2019521963A5 JP2018559205A JP2018559205A JP2019521963A5 JP 2019521963 A5 JP2019521963 A5 JP 2019521963A5 JP 2018559205 A JP2018559205 A JP 2018559205A JP 2018559205 A JP2018559205 A JP 2018559205A JP 2019521963 A5 JP2019521963 A5 JP 2019521963A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- inflammation
- composition
- group
- tsp1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 claims 8
- 102100023704 Spermatogenic leucine zipper protein 1 Human genes 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 7
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 7
- 206010061218 Inflammation Diseases 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 239000012190 activator Substances 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 239000000178 monomer Substances 0.000 claims 3
- 108010017447 4N1K peptide Proteins 0.000 claims 2
- 206010039705 Scleritis Diseases 0.000 claims 2
- 102100021119 Serine protease HTRA1 Human genes 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010015084 Episcleritis Diseases 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 208000007792 Orbital Pseudotumor Diseases 0.000 claims 1
- 208000035452 Orbital pseudotumour Diseases 0.000 claims 1
- 201000001949 Retinal Vasculitis Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 208000038018 age-related macular disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 claims 1
- 201000010668 orbital plasma cell granuloma Diseases 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022035726A JP2022078244A (ja) | 2016-05-10 | 2022-03-08 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
| JP2023180474A JP7822577B2 (ja) | 2016-05-10 | 2023-10-19 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16169072.2 | 2016-05-10 | ||
| EP16169072 | 2016-05-10 | ||
| EP17154452 | 2017-02-02 | ||
| EP17154452.1 | 2017-02-02 | ||
| PCT/EP2017/061151 WO2017194586A1 (en) | 2016-05-10 | 2017-05-10 | Agents that activate cd47 and their use in the treatment of inflammation |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022035726A Division JP2022078244A (ja) | 2016-05-10 | 2022-03-08 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
| JP2023180474A Division JP7822577B2 (ja) | 2016-05-10 | 2023-10-19 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521963A JP2019521963A (ja) | 2019-08-08 |
| JP2019521963A5 true JP2019521963A5 (https=) | 2020-05-07 |
| JP7537074B2 JP7537074B2 (ja) | 2024-08-21 |
Family
ID=58772857
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559205A Active JP7537074B2 (ja) | 2016-05-10 | 2017-05-10 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
| JP2022035726A Pending JP2022078244A (ja) | 2016-05-10 | 2022-03-08 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
| JP2023180474A Active JP7822577B2 (ja) | 2016-05-10 | 2023-10-19 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022035726A Pending JP2022078244A (ja) | 2016-05-10 | 2022-03-08 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
| JP2023180474A Active JP7822577B2 (ja) | 2016-05-10 | 2023-10-19 | Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11142548B2 (https=) |
| EP (1) | EP3454884B1 (https=) |
| JP (3) | JP7537074B2 (https=) |
| CA (1) | CA3023802C (https=) |
| WO (1) | WO2017194586A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3023802C (en) * | 2016-05-10 | 2025-02-04 | Inserm (Institut De La Sante Et De La Recherche Medicale) | ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION |
| EP3737370A4 (en) * | 2018-01-09 | 2021-12-15 | Brigham Young University | COMPOSITIONS AND METHODS OF TREATMENT OF PAIN WITH WOGONIN |
| JPWO2022113887A1 (https=) * | 2020-11-27 | 2022-06-02 | ||
| EP4329825A4 (en) * | 2021-04-26 | 2025-03-26 | President and Fellows of Harvard College | CD47 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEGENERATIVE EYE DISEASES |
| CN116831988A (zh) * | 2023-06-13 | 2023-10-03 | 南京鼓楼医院 | 一种载肽模拟物pkhb1的脂质体眼用制剂及其制备方法 |
| WO2026062098A1 (fr) | 2024-09-18 | 2026-03-26 | Sorbonne Universite | Nouvelles protéines activatrices de cd47 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US6001962A (en) | 1996-11-15 | 1999-12-14 | The Regents Of The University Of California | Modified Fas ligands |
| CA2226962A1 (en) | 1998-02-16 | 1999-08-16 | Marie Sarfati | Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection |
| DE69938451T2 (de) | 1998-06-18 | 2009-04-09 | Imed Ab | Fas peptide und antikörper zur modulierung von apoptosis |
| JP5431151B2 (ja) | 2006-07-13 | 2014-03-05 | ユニバーシティー オブ アイオワ リサーチ ファンデーション | 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬 |
| US20110237498A1 (en) * | 2008-12-19 | 2011-09-29 | Novartis Ag | Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
| CA2766039A1 (en) | 2009-06-29 | 2011-01-20 | The Board Of Regents Of The University Of Texas System | Arginase formulations and methods |
| EP2563359A1 (en) | 2010-04-30 | 2013-03-06 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
| HRP20221260T1 (hr) | 2010-05-14 | 2023-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizirana i kimerna monoklonska protutijela za cd47 |
| US20140127269A1 (en) | 2012-02-13 | 2014-05-08 | The Schepens Eye Research Institute, Inc. | Anti-Inflammatory Peptide Derived From Thrombospondin-1 and Uses Thereof |
| CN104519898A (zh) | 2012-06-06 | 2015-04-15 | 国家健康与医学研究院 | 用于治疗癌症的方法和药物组合物 |
| WO2014060517A1 (en) | 2012-10-17 | 2014-04-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (amd) |
| PL3087182T3 (pl) | 2013-12-23 | 2019-11-29 | Memorial Sloan Kettering Cancer Center | Sposoby i kompozycje do leczenia raka wykorzystujące środki oparte na kwasie peptydonukleinowym |
| EP2898896A1 (en) * | 2014-01-22 | 2015-07-29 | Université Pierre et Marie Curie (Paris 6) | Agents for use in the treatment of retinal inflammation |
| JP6613304B2 (ja) | 2014-09-17 | 2019-12-04 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 抗ｃｄ２７６抗体（ｂ７ｈ３） |
| WO2016061133A1 (en) | 2014-10-14 | 2016-04-21 | Riptide Bioscience, Inc. | Peptides having anti-inflammatory properties |
| FR3036620B1 (fr) * | 2015-05-27 | 2017-09-01 | Inst Biophytis | Utilisation de 3-desoxyanthocyanidines pour le traitement de maladies oculaires |
| CA3023802C (en) * | 2016-05-10 | 2025-02-04 | Inserm (Institut De La Sante Et De La Recherche Medicale) | ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION |
-
2017
- 2017-05-10 CA CA3023802A patent/CA3023802C/en active Active
- 2017-05-10 EP EP17725893.6A patent/EP3454884B1/en active Active
- 2017-05-10 WO PCT/EP2017/061151 patent/WO2017194586A1/en not_active Ceased
- 2017-05-10 US US16/300,438 patent/US11142548B2/en active Active
- 2017-05-10 JP JP2018559205A patent/JP7537074B2/ja active Active
-
2022
- 2022-03-08 JP JP2022035726A patent/JP2022078244A/ja active Pending
-
2023
- 2023-10-19 JP JP2023180474A patent/JP7822577B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521963A5 (https=) | ||
| JP6086067B2 (ja) | Ｇｉｐレセプター活性を示すグルカゴンアナローグ | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| CN104583233B (zh) | 表现出gip受体活性的胰高血糖素的类似物 | |
| TWI599575B (zh) | 表現ｇｉｐ受體活性之胰高血糖素類似物 | |
| TWI501775B (zh) | 升糖素／ｇｌｐ－１受體共促效劑 | |
| JP2018538356A5 (https=) | ||
| JP2017528419A5 (https=) | ||
| JP2018515088A5 (https=) | ||
| JP2017500018A5 (https=) | ||
| WO2014152460A2 (en) | Prodrugs with prolonged action | |
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| JP2019507589A5 (https=) | ||
| JP2017527272A5 (https=) | ||
| JP2023179752A5 (https=) | ||
| JP2019533722A5 (https=) | ||
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| JP2016536357A5 (https=) | ||
| WO2015138604A1 (en) | Compositions and methods for treating eye infections and disease | |
| MX2025001402A (es) | Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| WO2006087550A3 (en) | Amyloid-binding peptides, analogues and uses thereof | |
| KR20220143702A (ko) | Ras 단백질을 표적화하는 분자 | |
| JP2019038772A5 (https=) | ||
| WO2018156892A1 (en) | Peptide inhibitors of transcription factor aggregation |